Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension

Kidney International

Volumn 88, Issue 3, 2015, Pages 622-632

  Sim, John J ^a   Bhandari, Simran K ^a   Shi, Jiaxiao ^b   Reynolds, Kristi ^b   Calhoun, David A ^c   Kalantar Zadeh, Kamyar ^d   Jacobsen, Steven J ^b  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cardiovascular outcomes; mortality outcomes; renal outcomes; resistant hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT;

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESISTANT HYPERTENSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHI SQUARE DISTRIBUTION; COMPLICATION; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; HEART FAILURE; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84940795361     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.142     Document Type: Article

References (49)

1. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998; 339: 1957-1963.
2. Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006; 47: 345-351.
3. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001; 135: 825-834.
4. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010; 303: 2043-2050.
5. Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011; 124: 1046-1058.
6. Kumbhani DJ, Steg PG, Cannon CP, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013; 34: 1204-1214.
7. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011; 57: 1076-1080.
8. Sarafidis PA. Epidemiology of resistant hypertension. J Clin Hypertens (Greenwich) 2011; 13: 523-528.
9. Sim JJ, Bhandari SK, Shi J, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proceed. 2013; 88: 1099-1107.
10. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125: 1635-1642.
11. Isaksson H, ÖStergren J. Prognosis in therapy-resistant hypertension. J Intern Med. 1994; 236: 643-649.
12. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008; 168: 2340-2346.
13. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007; 49: 839-845.
14. Muxfeldt ES, Cardoso CR, Dias VB, et al. Prognostic impact of the ambulatory arterial stiffness index in resistant hypertension. J Hypertens. 2010; 28: 1547-1553.
15. Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens. 2001; 19: 2063-2070.
16. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011; 57: 898-902.
17. Bangalore S, Fayyad R, Laskey R, et al. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med. 2014; 127: 71-81 e1.
18. Smith SM, Gong Y, Handberg E, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014; 32: 635-643.
19. De Nicola L, Gabbai FB, Agarwal R, et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol. 2013; 61: 2461-2467.
20. Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005; 18: 1422-1428.
21. O'Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol. 2007; 18: 2758-2765.
22. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006; 368: 666-678.
23. Jin CN, Liu M, Sun JP, et al. The prevalence and prognosis of resistant hypertension in patients with heart failure. PLoS One. 2014; 9: e114958.
24. Acharya T, Tringali S, Singh M, et al. Resistant hypertension and associated comorbidities in a veterans affairs population. J Clin Hypertens (Greenwich) 2014; 16: 741-745.
25. Sim JJ, Handler J, Jacobsen SJ, et al. Systemic implementation strategies to improve hypertension: the Kaiser Permanente Southern California Experience. Can J Cardiol. 2014; 30: 544-552.
26. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008; 117: e510-e526.
27. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003; 289: 2560-2572.
28. Cifkova R, Erdine S, Fagard R, et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens. 2003; 21: 1779-1786.
29. Gifford JRAYW, Tarazi RC. Resistant hypertension: diagnosis and management. Ann Intern Med. 1978; 88: 661-665.
30. Fung V, Huang J, Brand R, et al. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther. 2007; 29: 972-984.
31. Gu Q, Burt VL, Dillon CF, et al. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation. 2012; 126: 2105-2114.
32. Banegas JR, Navarro-Vidal B, Ruilope LM, et al. Trends in hypertension control among the older population of Spain from 2000 to 2001 to 2008 to 2010: role of frequency and intensity of drug treatment. Circ Cardiovasc Qual Outcomes. 2015; 8: 67-76.
33. Sim JJ, Bhandari SK, Shi J, et al. Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system. Am J Hypertens. 2012; 25: 379-388.
34. James PA, Oparil S, Carter BL, et al. 2014Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311: 507-520.
35. Bangalore S, Messerli FH, Wun CC, et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010; 31: 2897-2908.
36. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1575-1585.
37. Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol. 2014; 64: 588-597.
38. Group SPSS, Benavente OR, Coffey CS, Conwit R, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013; 382: 507-515.
39. Kovesdy CP, Bleyer AJ, Molnar MZ, et al. Blood pressure and mortality in U. S. Veterans with chronic kidney disease: a cohort study. Ann Inter Med. 2013; 159: 233-242.
40. Calhoun DA, Booth JN 3rd, Oparil S, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014; 63: 451-458.
41. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993; 328: 914-921.
42. Wright JT Jr., Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293: 1595-1608.
43. Egan BM, Basile JN, Rehman SU, et al. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009; 22: 792-801.
44. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001; 345: 1291-1297.
45. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-Analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903-1913.
46. Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012; 16: 37-41.
47. Bhandari SK, Pashayan S, Liu IL, et al. 25-hydroxyvitamin D levels and hypertension rates. J Clin Hypertens. 2011; 13: 170-177.
48. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619.
49. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604-612.